Solid tumor biotech’s polymer nanoparticle-drug conjugate clears early-stage hurdle, sparking PhII plans
Dantari’s drug conjugate asset has produced positive data as both a monotherapy and in combination with a PARP inhibitor in an early-stage breast cancer trial, paving the way for a Phase II test.
The biotech’s Phase I dose escalation trial studied DAN-222 as a single agent and in combination with GSK’s Zejula in 30 metastatic HER2-negative breast cancer patients with a median of six prior lines of therapy. Results from the trial come one year after Dantari raised $47 million in a Series A round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.